Plasma microRNA-19a as a potential biomarker for esophageal squamous cell carcinoma diagnosis and prognosis
| Autor: | Qing Luo, Falin Chen, Yuanhui Su, Qing Hu, Huayue Lin, Hongbing Duan, Yizhen Fang, Zhongying Zhang, Zanxi Fang, Bai Yongying |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology medicine.medical_specialty Esophageal Neoplasms Clinical Biochemistry Down-Regulation Esophageal squamous cell carcinoma 03 medical and health sciences 0302 clinical medicine Recurrence Internal medicine Drug Discovery microRNA Biomarkers Tumor medicine Humans In patient Neoplasm Metastasis Aged Neoplasm Staging Aged 80 and over Plasma samples business.industry Biochemistry (medical) Benign lesion Middle Aged Prognosis digestive system diseases MicroRNAs 030104 developmental biology 030220 oncology & carcinogenesis Potential biomarkers Cytokeratin 19 fragment Carcinoma Squamous Cell Biomarker (medicine) Female Esophageal Squamous Cell Carcinoma business |
| Zdroj: | Biomarkers in Medicine. 11:431-441 |
| ISSN: | 1752-0371 1752-0363 |
| Popis: | Aim: To investigate whether plasma miR-19a can serve as a biomarker for esophageal squamous cell carcinoma (ESCC) diagnosis and prognosis. Materials & methods: Plasma samples from 89 ESCC, 45 benign lesion patients and 80 healthy controls were subjected to RT-qPCR analyses for miR-19a. In addition, plasma samples from 30 patients were collected before and after surgery for the same analyses. Results: Plasma miR-19a was significantly increased in ESCC patients compared with healthy controls. The sensitivity of miR-19a for early stages of ESCC was 68.09%. Combination of miR-19a and cytokeratin 19 fragment 21–1 (Cyfra21-1) further improved the sensitivity to 78.70%. Moreover, plasma miR-19a level was decreased in patients after surgery. Conclusion: Plasma miR-19a may serve as a potential biomarker that complements Cyfra21-1 in detecting early stages of ESCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|